Clareo Health | Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Envisia Therapeutics
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of either ocular hypertension or open angle glaucoma in both eyes.
Are currently treated with topical PGA for ocular hypertension in both eyes.
Patients who in the opinion of the Investigator: have an IOP in both eyes that is considered to be adequately controlled, can be safely withdrawn from IOP medications in both eyes during the washout period, and who are not considered to be at significant risk for disease progression throughout the trial.
You may not be if
Eye surgery (including cataract surgery) within the past 3 months.
